Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
An increasing rate of antidepressant trials fail due to large placebo responses. This analysis aimed to identify variables influencing signal detection in clinical trials of major depressive disorder. Patient-level data of randomized patients with a duloxetine dose ≥ 60 mg/day were obtained from Lilly. Total scores of the Hamilton Depression Rating scale (HAM-D) were used as efficacy endpoints. In total, 4661 patients from 14 studies were included in the analysis. The overall effect size (ES), based on the HAM-D total score at endpoint, between duloxetine and placebo was -0.272. Although no statistically significant interactions were found, the following results for factors influencing ES were seen: a very low ES (-0.157) in patients in the lowest baseline HAM-D category and in patients recruited in the last category of the recruitment period (-0.122). A higher ES in patients recruited in centers with a site-size at but not more than 2.5 times the average site-size for the study (-0.345). Study characteristics that resulted in low signal detection in our database were: <80% study completers, a HAM-D placebo response >5 points, a high variability of placebo response (SD > 7 points HAM-D), >6 post baseline visits per study, and use of an active control drug. Simpler trial designs, more homogeneous and mid-sized study sites, a primary analysis based on a higher cutoff blinded to investigators to avoid the influence of score inflation in mild patients and, if possible, studies without an active control group could lead to a better signal detection of antidepressive efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Khan, A., Leventhal, R. M., Khan, S. R., & Brown, W. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00007 · Cited by 456
Detke, M. J., Lu, Y., Goldstein, D. J., Hayes, J. R., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0407 · Cited by 384
Duloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0309 · Cited by 334
Raskin, J., Wiltse, C. G., Siegal, A., Sheikh, J., Xu, J., Dinkel, J. J., Rotz, B. T., & Mohs, R. C. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.900 · Cited by 329
Goldstein, D. J., Lu, Y., Detke, M. J., Wiltse, C., Mallinckrodt, C., & Demitrack, M. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000132448.65972.d9 · Cited by 314
Zimmerman, M., Chelminski, I., & Posternak, M. A. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1370 · Cited by 144
Evidence review: efficacy and effectiveness of antidepressant treatment in primary care
Simon, G. E. (2002) · General Hospital Psychiatry · doi:10.1016/s0163-8343(02)00198-6 · Cited by 132
Cited by
Mossman, S. A., Luft, M. J., Schroeder, H. K., Varney, S. T., Fleck, D. E., Barzman, D. H., Gilman, R., DelBello, M. P., & Strawn, J. R. (2017) · Annals of Clinical Psychiatry · doi:10.1177/104012371702900404 · Cited by 471
Schedlowski, M., Enck, P., Rief, W., & Bingel, U. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009423 · Cited by 323
“…et al., 1999), unbalanced randomization may increase the overall placebo response in RCTs, as shown in trials on depression (Papakostas and Fava, 2009; Sinyor et al., 2010; Mancini et al., 2014), schizophrenia (Woods et al., 2005; Mallinckrodt et al., 2010), and psychosis (Agid et al., 2013).”
BackgroundFurukawa, T. A., Cipriani, A., Atkinson, L. Z., Leucht, S., Ogawa, Y., Takeshima, N., Hayasaka, Y., Chaimani, A., & Salanti, G. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30307-8 · Cited by 219
Tabuteau, H., Jones, A., Anderson, A., Jacobson, M., & Iosifescu, D. V. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21080800 · Cited by 140
Placebo effects in psychotherapy: a framework
Enck, P., & Zipfel, S. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00456 · Cited by 115
Metadata
- Authors
- Mancini, M., Wade, A. G., Perugi, G., Lenox-Smith, A., & Schacht, A.
- Venue
- Journal of Psychiatric Research
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 51
- Pages
- 21-29
- ISSN
- 0022-3956 (ISSN-L)
- OpenAlex
- W1999820418
- Cited by
- 28
- References
- 15
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants. https://app.cochat.ai/papers/10.1016/j.jpsychires.2014.01.001
- The paper
- Mancini, M., Wade, A. G., Perugi, G., Lenox-Smith, A., & Schacht, A. (2014). Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants. Journal of Psychiatric Research. https://doi.org/10.1016/j.jpsychires.2014.01.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.